Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
POSIMIR®
Sort By
Newest First
Sign in
1 / 1
1 / 1
Licensing Agreement
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
DURECT Corporation
PR-M05-18-NI-042
May 10, 2018
